Bispecific therapies represent a class of drug with two binding sites directed at two different antigens or epitopes. This dual action makes bispecific therapies a promising approach to improve target specificity. These therapies can be designed to recruit and activate immune cells, interfere with receptor signaling, and inactivate signaling ligand. Drug manufacturers are extensively exploring bispecific therapies either as monotherapy or in combination with other targeted immunotherapies. To date, six bispecific therapies have been approved across the G7 and China, for both hematological malignancies and solid tumors. This Special Topics report provides a comprehensive view of the current bispecific therapy landscape and pipeline, with coverage of therapies in early-phase through late-phase development across a range of oncology indications.
- What is the current landscape for approved bispecific therapies? What are the key trends? What impact will these treatments have in their respective oncology indications?
- What does the bispecific therapy pipeline look like by phase of development? What are the key classes of therapies? What are the key developers? In which geographies is development focused?
- What are the trends in the development of bispecific therapies? In which oncology indications most bispecific therapies are being investigated? What are the key targets in solid and hematological tumors?
United States, EU5, Japan, and China
PRIMARY AND SECONDARY MARKET RESEARCH
In-depth interviews with six key opinion leaders (hematologist-oncologists); analysis of industry and company reports; peer-reviewed journals; pipeline databases (Cortellis, ClinicalTrials.gov); industry / scientific conferences; news; media
KEY DRUGS COVERED
Blincyto, Kadulini, Kimmtrak, Lunsumio, Rybrevant, and Tecvayli
Therapies in Phase III development (e.g., glofitamab, elranatamab, epcoritamab)
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive pipeline analysis of the bispecific therapy landscape in relevant oncology indications.
- Bispecific Therapies - Special Topics - Special Topics: Bispecific Therapies (G7 And China)
- Bispecific Therapies in Oncology: Pipeline Analysis
Laura Vinuesa, D.V.M., M.Sc.
Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master’s degree in clinical research and pharmaceutical medicine from EPHOS Business School in Madrid.
Liseth Parra, Ph.D., is an analyst on the Oncology team at Clarivate. She has extensive background in oncology research and market analysis. She completed a postdoctoral fellowship in oncology at Brigham and Women’s Hospital in Boston, along with commercial work as an oncology research analyst for Kantar Health and as an independent consultant. She also worked as a research fellow at the Novartis Institutes for BioMedical Research in Basel, Switzerland, and at the Fritz Lipmann Institute in Jena, Germany. Dr. Parra completed her doctorate in neurosciences at the University of California in San Diego.